How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

678 results for

Sibutramine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

83. Guidelines for the Primary Prevention of Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association

lifestyle goals, including normal weight, were met. 279 The Sibutramine Cardiovascular Outcomes (SCOUT) trial followed up 10 000 patients with CVD or type 2 diabetes mellitus and found that even modest weight loss reduced cardiovascular mortality in the following 4 to 5 years. 280 Reduction in body weight improves control of hypertension. A meta-analysis of 25 trials showed mean SBP and DBP reductions of 4.4 and 3.6 mm Hg, respectively, with a 5.1-kg weight loss. 281 The US Preventive Services Task

2014 American Heart Association

85. Observational study: Metformin associated with better cardiovascular outcomes than other glycaemic therapies

glycaemic therapies Zachary T Bloomgarden Statistics from Altmetric.com Context A question exists as to whether the outcome of glycaemic treatment of diabetes varies with the agent used; speculation surrounds whether metformin might be preferable to other treatments. Methods Ghotbi and colleagues performed an epidemiological analysis of 8192 obese patients with diabetes at increased cardiovascular risk participating in the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Mortality and a combined (...) cardiovascular outcome of non-fatal myocardial infarction, non-fatal stroke, resuscitation after cardiac arrest or cardiovascular death were compared among those receiving one of the following interventions: no pharmacological glycaemic treatment, metformin monotherapy, insulin monotherapy, sulfonylurea monotherapy, metformin plus sulfonylurea and metformin plus insulin. Each group consisted of approximately 1000–1500 participants, randomised to either sibutramine or control (the main purpose of the trial

2014 Evidence-Based Medicine

90. Overweight and Obesity in Adults: Guideline For the Management of

K, Sundström J, Neovius K, et al. Long-term changes in blood pressure following orlistat and sibutramine treatment:a meta- analysis. Obes Rev 2010;11:777–91. 22. Look AHEAD Research Group, Pi-Sunyer X, Blackburn G, et al. Reduction in weight and cardiovascular disease risk factors in in- dividuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care 2007;30:1374–83. 23. Look AHEAD Research Group, Wing RR. Long-term effects of a lifestyle intervention on weight

2013 American College of Cardiology

92. Centrally-acting drugs for obesity cause more harm than good

products (16 trials with 24,555 participants) – three (lorcaserin, naltrexone-bupropion and phentermine-topiramate ) of which are currently available and two (rimonabant and sibutramine) withdrawn from the market because of serious adverse reactions. Centrally acting medicines increased the chance of losing at least 5% of body weight, but their use was associated with increased risk of harms and discontinuation because of these harms. In particular, the risk of nervous and psychiatric adverse events

2018 Evidence-Based Medicine blog

94. A Phase IV Study in Drug-Naive Patients With T2DM in China

affect the interpretation of efficacy or safety data. History of bone fracture secondary to diagnosed severe osteoporosis. Currently unstable or serious cardiovascular, renal, hepatic, hematologic, oncologic, endocrine, psychiatric, or rheumatic diseases as judged by the Investigator. Replacement or chronic systemic corticosteroid therapy, defined as any dose of systemic corticosteroid taken for >4 weeks within 3 months before enrollment visit. Administration of sibutramine, phentermine, orlistat

2017 Clinical Trials

95. Exogenous T3 toxicosis following consumption of a contaminated weight loss supplement Full Text available with Trip Pro

a weight loss product online from India which supposedly contained sibutramine. He provided one of the tablets and laboratory analysis confirmed the presence of T3 in the tablet. Full symptomatic resolution and normalised thyroid function ensued upon discontinuation of the supplement.Free tri-iodothyronine (T3) measurement may be useful in the presence of symptoms suggestive of thyrotoxicosis with discordant thyroid function tests.Thyroid uptake scanning can be a useful aid to differentiating exogenous

2017 Endocrinology, diabetes & metabolism case reports

96. Ferulic acid lowers body weight and visceral fat accumulation via modulation of enzymatic, hormonal and inflammatory changes in a mouse model of high-fat diet-induced obesity Full Text available with Trip Pro

male Swiss mice, weighing 20-25 g (n=6-8 per group) were fed a normal diet (ND) or HFD, treated orally or not with either FA (10 mg/kg) or sibutramine (10 mg/kg) for 15 weeks and at the end of this period, the body weights of animals, visceral fat accumulation, plasma levels of glucose and insulin hormone, amylase and lipase activities, the satiety hormones ghrelin and leptin, and tumor necrosis factor-α (TNF-α) and monocyte chemoattractant protein-1 (MCH-1) were analyzed. Results revealed that FA (...) could effectively suppress the HFD-associated increase in visceral fat accumulation, adipocyte size and body weight gain, similar to sibutramine, the positive control. FA also significantly (P<0.05) decreased the HFD-induced elevations in serum lipid profiles, amylase and lipase activities, and the levels of blood glucose and insulin hormone. The markedly elevated leptin and decreased ghrelin levels seen in HFD-fed control mice were significantly (P<0.05) reversed by FA treatment, almost reaching

2017 Brazilian Journal of Medical and Biological Research

97. Effect of Combined Morphine and Duloxetine on Chronic Pain

, lithium, linezolid, tramadol (Ultram), St. John's Wort, central nervous system (CNS) stimulants such as amphetamine, methylphenidate, methamphetamine, phentermine, diethylpropion, sibutramine, cocaine, or thioridazine. Subject has uncontrolled narrow-angle glaucoma. Subject has sensory deficits on arms or Raynaud's Syndrome. Subject has a pending litigation related to chronic pain condition. Subject is on methadone or suboxone treatment for addiction. Contacts and Locations Go to Information from

2017 Clinical Trials

98. Effect of Resistant Starch on Insulin Sensitivity and Beta Cell Function in Subjects With Prediabetes

, the administration of a treatment that may affect the interpretation of the efficacy and safety data. Treatment with any oral antidiabetic medicinal product and / or herbal preparations / non-prescription medicines that may affect glycemic control within 12 weeks prior to screening. Chronic treatment with oral or parenteral corticosteroids (> 7 consecutive days of treatment) within 4 weeks prior to screening. Treatment with weight-reducing agents (eg, orlistat, sibutramine, topiramate, bupropion) within the last

2017 Clinical Trials

99. Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus

(such as orlistat, sibutramine, rimonabant, phenylpropanol or chlorpheniramine) that promote weight loss within 3 months before study; Take any medications that may affect test results, such as antibiotics, non-steroidal anti-inflammatory drugs, antacids containing aluminum or magnesium, diuretics, anticoagulants, central nervous system inhibitors, systemic corticosteroids, medications to slow down the gastrointestinal motility, and any drug that may possibly affect the absorption of the drug within 2 weeks

2017 Clinical Trials

100. Targeted Enteral Nutrient Delivery: A Prospective Randomized Study

, and lithium) thioridazine, clozapine, Currently using or have used within three months prior to screening for this trial: pramlintide, sibutramine, orlistat, zonisamide, topiramate or phenteremine (either by prescription or as part of a clinical trial) Simultaneous participation in any other clinical trial of an investigational drug The receipt of any investigational product within four weeks prior to screening for this trial Herbal supplements or over-the-counter medications Diet attempts using herbal

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>